Abstract:Cancer immunotherapy has become a research hotspot in recent years. A variety of targets were developed for small molecule immuno-oncology agents, including retinoic acid-related orphan receptor gamma t (RORγt), chemokine receptor, stimulator of interferon genes (Sting), indoleamine 2,3-dioxygenase (IDO), toll-like receptors (TLR), etc. Among them, the retinoic acid receptor-related orphan receptor γt (RORγt) has gradually attracted more attention in these years. In particular, LYC-55716 (cintirorgon), a small molecule RORγt agonist developed by Lycera, has entered the phase II clinical study. In this work, starting from compound 7, compound 28 was obtained after 4 rounds of compound design, synthesis and SAR studies, which had an EC50 of 0.021 ± 0.002 μM in dual Fluorescence Resonance Energy Transfer (dual-FRET) assay and an EC50 of 0.021 ± 0.002 μM in mouse Th17 cell differentiation assay. It indicated that compound 28 had excellent RORγt agonistic activity and was expected to be developed as a new type of small molecule drug for cancer immunotherapy. The molecular dynamic simulation revealed that the agonist 28 formed a strong HYF triplet intramolecular interaction to stabilize H12, which helped RORγt to form the protein-binding site and therefore made the receptor ready to recruit coactivator. When the inverse agonist s27 bound with RORγt, the steric hindrance between s27 and H479 caused the destruction of the HYF triplet, leading to the collapse of H12, thus the transcription function of RORγt was interrupted due to the failure of recruiting a coactivator molecule. The triplet HYF in RORγt and the rigidity of 28 and s27 were identified to be the structural determinants for the functional switch of RORγt.

Discovery of <i>tert</i>-amine-based RORt agonists

Discovery of tert-amine-based RORγt agonists.

Discovery of Biaryl Amide Derivatives As Potent, Selective, and Orally Bioavailable RORγt Agonists for Cancer Immunotherapy.

Discovery of tetrahydroquinolines and benzomorpholines as novel potent RORt agonists

Discovery of Novel N-sulfonamide-tetrahydroisoquinolines As Potent Retinoic Acid Receptor-Related Orphan Receptor Γt Agonists

Discovery of Tetrahydroquinolines and Benzomorpholines As Novel Potent Ror Gamma T Agonists

Discovery of Aryl-Substituted Indole and Indoline Derivatives As RORγt Agonists

Discovery of Tertiary Amine and Indole Derivatives as Potent RORγt Inverse Agonists.

Discovery of novel triazine derivatives as potent retinoic acid receptor-related orphan receptor γt (RORγt) inverse agonists

Discovery of N-indanyl Benzamides As Potent RORγt Inverse Agonists

Discovery of tetrahydroquinolines and benzomorpholines as novel potent RORγt agonists.

Discovery of N -(4-aryl-5-aryloxy-thiazol-2-yl)-amides as potent RORγt inverse agonists

Discovery of Novel N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides As Potent RORγt Inhibitors

Optimization of carbazole carboxamide RORγt agonists: Challenges in improving the metabolic stability and maintaining the agonistic activity

Increasing human Th17 differentiation through activation of orphan nuclear receptor retinoid acid-related orphan receptor γ (RORγ) by a class of aryl amide compounds.

Development and therapeutic potential of allosteric retinoic acid receptor-related orphan receptor ?t (ROR?t) inverse agonists for autoimmune diseases

Discovery of Carbazole Carboxamides As Novel RORγt Inverse Agonists.

Retinoic Acid Receptor-Related Orphan Receptor Γt (rorγt) Agonists As Potential Small Molecule Therapeutics for Cancer Immunotherapy.

Molecular Mechanism of Action of RORγt Agonists and Inverse Agonists: Insights from Molecular Dynamics Simulation

Discovery of Novel Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) Inhibitors for Cancer Treatment

From RORγt Agonist to Two Types of RORγt Inverse Agonists.